Disease risk scores for skin cancers.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
08 01 2021
Historique:
received: 11 06 2020
accepted: 05 11 2020
entrez: 9 1 2021
pubmed: 10 1 2021
medline: 26 1 2021
Statut: epublish

Résumé

We trained and validated risk prediction models for the three major types of skin cancer- basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma-on a cross-sectional and longitudinal dataset of 210,000 consented research participants who responded to an online survey covering personal and family history of skin cancer, skin susceptibility, and UV exposure. We developed a primary disease risk score (DRS) that combined all 32 identified genetic and non-genetic risk factors. Top percentile DRS was associated with an up to 13-fold increase (odds ratio per standard deviation increase >2.5) in the risk of developing skin cancer relative to the middle DRS percentile. To derive lifetime risk trajectories for the three skin cancers, we developed a second and age independent disease score, called DRSA. Using incident cases, we demonstrated that DRSA could be used in early detection programs for identifying high risk asymptotic individuals, and predicting when they are likely to develop skin cancer. High DRSA scores were not only associated with earlier disease diagnosis (by up to 14 years), but also with more severe and recurrent forms of skin cancer.

Identifiants

pubmed: 33420020
doi: 10.1038/s41467-020-20246-5
pii: 10.1038/s41467-020-20246-5
pmc: PMC7794415
doi:

Types de publication

Journal Article Observational Study Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

160

Investigateurs

Michelle Agee (M)
Robert K Bell (RK)
Katarzyna Bryc (K)
Sarah L Elson (SL)
David A Hinds (DA)
Karen E Huber (KE)
Aaron Kleinman (A)
Nadia K Litterman (NK)
Jennifer C McCreight (JC)
Matthew H McIntyre (MH)
Joanna L Mountain (JL)
Elizabeth S Noblin (ES)
Carrie A M Northover (CAM)
J Fah Sathirapongsasuti (JF)
Olga V Sazonova (OV)
Janie F Shelton (JF)
Suyash Shringarpure (S)
Chao Tian (C)
Joyce Y Tung (JY)
Vladimir Vacic (V)

Références

J Invest Dermatol. 2015 May;135(5):1377-1384
pubmed: 25548858
Hum Mol Genet. 2018 Dec 1;27(23):4145-4156
pubmed: 30060076
Nat Commun. 2017 Sep 19;8(1):599
pubmed: 28928442
Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1450-63
pubmed: 24895414
Cancer Discov. 2018 Jul;8(7):803-811
pubmed: 29907587
Int J Cancer. 2019 May 15;144(10):2453-2464
pubmed: 30414346
PLoS One. 2015 Mar 24;10(3):e0122662
pubmed: 25803691
N Engl J Med. 2018 Jul 26;379(4):363-374
pubmed: 30044931
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
Nat Commun. 2016 Aug 19;7:12510
pubmed: 27539887
Cancer Epidemiol. 2017 Feb;46:66-72
pubmed: 28039770
Br J Cancer. 1979 Nov;40(5):774-81
pubmed: 508580
Nat Rev Genet. 2016 Jul;17(7):392-406
pubmed: 27140283
Natl Vital Stat Rep. 2019 Jun;68(7):1-66
pubmed: 32501200
Ann Appl Stat. 2016 Mar;10(1):286-304
pubmed: 27158296
Nat Genet. 2017 Aug;49(8):1174-1181
pubmed: 28692066
JAMA Dermatol. 2015 Oct;151(10):1081-6
pubmed: 25928283
J Dermatol Sci. 2016 Dec;84(3):330-339
pubmed: 27663092
Br J Dermatol. 2015 Dec;173(6):1540-3
pubmed: 26134854
Epidemiology (Sunnyvale). 2016 Apr;6(2):
pubmed: 27274911
N Engl J Med. 2017 Mar 9;376(10):986-990
pubmed: 28273020
BMC Med Inform Decis Mak. 2018 Dec 29;18(1):139
pubmed: 30594159
PLoS Genet. 2019 Jun 13;15(6):e1008202
pubmed: 31194742
Eur J Epidemiol. 2015 Feb;30(2):159-62
pubmed: 25600298
Oncol Lett. 2017 May;13(5):3787-3792
pubmed: 28521479
Br J Dermatol. 2019 Dec;181(6):1146-1155
pubmed: 30908599
PLoS One. 2012;7(4):e34267
pubmed: 22509285
NPJ Precis Oncol. 2019 Jan 28;3:3
pubmed: 30701196
J Invest Dermatol. 2017 Aug;137(8):1700-1708
pubmed: 28414022
Nat Genet. 2019 Apr;51(4):584-591
pubmed: 30926966
Nat Genet. 2018 Mar;50(3):322-328
pubmed: 29511284
Int J Cancer. 2012 Jul 15;131(2):E149-55
pubmed: 21989791
Sci Rep. 2016 Nov 29;6:37691
pubmed: 27898109
Nat Genet. 2018 Sep;50(9):1219-1224
pubmed: 30104762
JAMA. 2016 Jul 26;316(4):429-35
pubmed: 27458948
Arch Dermatol. 2004 Jun;140(6):730-5
pubmed: 15210466

Auteurs

Pierre Fontanillas (P)

23andMe Inc., 223N Mathilda Ave, Sunnyvale, CA, 94086, USA. pfontanillas@23andme.com.

Babak Alipanahi (B)

23andMe Inc., 223N Mathilda Ave, Sunnyvale, CA, 94086, USA.

Nicholas A Furlotte (NA)

23andMe Inc., 223N Mathilda Ave, Sunnyvale, CA, 94086, USA.

Michaela Johnson (M)

23andMe Inc., 223N Mathilda Ave, Sunnyvale, CA, 94086, USA.

Catherine H Wilson (CH)

23andMe Inc., 223N Mathilda Ave, Sunnyvale, CA, 94086, USA.

Steven J Pitts (SJ)

23andMe Inc., 223N Mathilda Ave, Sunnyvale, CA, 94086, USA.

Robert Gentleman (R)

23andMe Inc., 223N Mathilda Ave, Sunnyvale, CA, 94086, USA.

Adam Auton (A)

23andMe Inc., 223N Mathilda Ave, Sunnyvale, CA, 94086, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH